Balyasny Asset Management LLC Exagen Inc. Transaction History
Balyasny Asset Management LLC
- $72.4 Billion
- Q3 2025
A detailed history of Balyasny Asset Management LLC transactions in Exagen Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 723,428 shares of XGN stock, worth $6.55 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
723,428
Previous 718,782
0.65%
Holding current value
$6.55 Million
Previous $5.02 Million
57.44%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding XGN
# of Institutions
64Shares Held
8.96MCall Options Held
25.7KPut Options Held
0-
Rtw Investments, LP New York, NY1.7MShares$15.4 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA734KShares$6.64 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA675KShares$6.11 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO552KShares$4.99 Million0.15% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY519KShares$4.7 Million0.04% of portfolio
About EXAGEN INC.
- Ticker XGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 16,260,400
- Market Cap $147M
- Description
- Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...